Similar articles

• The FDA and drug safety: a proposal for sweeping changes.

  Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. Furberg CD, et al. Arch Intern Med. 2006 Oct 9;166(18):1938-42. doi: 10.1001/archinte.166.18.1938. Arch Intern Med. 2006. PMID: 17030825
• The FDA's drug review process: ensuring drugs are safe and effective.

  Meadows M. Meadows M. FDA Consum. 2002 Jul-Aug;36(4):19-24. FDA Consum. 2002. PMID: 12184298 No abstract available.
• When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.

  Woodcock J. Woodcock J. FDA Consum. 1999 Sep-Oct;33(5):8-11, 13. FDA Consum. 1999. PMID: 10522164 No abstract available.
• The FDA's new oncology office.

  Pazdur R. Pazdur R. Clin Adv Hematol Oncol. 2005 Aug;3(8):612-3. Clin Adv Hematol Oncol. 2005. PMID: 16167044 Review. No abstract available.
• Promoting, improving and accelerating the drug development and approval processes.

  Graul AI. Graul AI. Drug News Perspect. 2008 Jan-Feb;21(1):36-43. Drug News Perspect. 2008. PMID: 18301808 Review.